A Randomized Controlled Trial of Sequential Pegylated Interferon-α and Telbivudine or Vice Versa for 48 Weeks in Hepatitis B E Antigen-Negative Chronic Hepatitis B

Abstract

Background

Short-term treatment for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B remains unsatisfactory. The aim of our study was to compare the efficacy and safety of two sequential regimens of pegylated interferon (PEG-IFN)-α and telbivudine (LdT).

Methods

Adult patients with biopsy-proven HBeAg-negative chronic hepatitis B, elevated alanine aminotransferase (ALT) and serum HBV DNA≥2,000 IU/ml were randomized 1:1 at baseline to receive PEG-IFN 180 μg/week for 24 weeks followed by LdT 600 mg/day for 24 weeks (PEG-IFN first), or vice versa (LdT first), plus 24-week follow-up; individuals with HCV, HDV or HIV coinfections and lamivudine resistance were excluded. Primary end points were serum HBV DNA<2,000 IU/ml and normal ALT at week 72.

Results

A total of 30 patients (86% male, median age 48 years) were enrolled: mean ±sdbaseline serum HBV DNA was 5.56 ±1.4 log IU/ml and ALT was 2.9 ±2.5x upper limit of normal. At end of follow-up (week 72), HBV DNA<2,000 IU/ml was achieved in 13.3% of participants in the PEG-IFN first group versus 46.7% of those in the LdT first group (P=0.046). Mean ±sdALT levels were significantly lower in the LdT first group (1.3 ±0.9 versus 3.2 ±2.7x upper limit of normal; P=0.03). PEG-IFN dose was reduced in 2 (7%) patients and 1 (7%) patient dropped out due to myalgia.

Conclusions

Sequential treatment with 24 weeks PEG-IFN followed or preceded by 24 weeks of LdT is safe. Virological response rate at week 72 was significantly higher in patients treated with LdT followed by PEG-IFN than vice versa. A sequential antiviral regimen of LdT followed by PEG-IFN, if confirmed in larger series, could improve response rates compared with standard PEG-IFN monotherapy.

References

Alter

M.J.

Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23: 39–46.

Kao

J.H.

, Chen

D.S.

Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395–403.

Lavanchy

Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 Suppl 1: S1–S3.

Custer

, Sullivan

S.D.

, Hazlet

T.K.

, Iloeje

, Veenstra

D.L.

, Kowdley

K.V.

Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 Suppl 3: S158–S168.

World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services. Geneva: WHO 2001.

Burra

, Smedile

, Angelico

, Ascione

, Rizzetto

Liver transplantation in Italy: current status. Study Group on Liver Transplantation of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2000; 32: 249–256.

Angelico

, Cillo

, Fagiuoli

Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155–164.

Piccolo

, Lenci

, Telesca

Patterns of chronic hepatitis B in Central Italy: a cross-sectional study. Eur J Public Health 2010; 20: 711–713.

Stroffolini

, Almasio

P.L.

, Sagnelli

, Mele

, Gaeta

G.B.

Evolving clinical landscape of chronic hepatitis B: a multicenter Italian study. J Med Virol 2009; 81: 1999–2006.

10.

Dal Molin

, Poli

, Crocè

L.S.

C. Hepatitis B virus genotypes, core promoter variants, and precore stop codon variants in patients infected chronically in North-Eastern Italy. J Med Virol 2006; 78: 734–740.

11.

Enomoto

, Tamori

, Nishiguchi

Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 2006; 52: 43–47.

12.

Erhardt

, Blondin

, Hauck

Response to interferon alpha is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 1009–1013.

13.

Brunetto

M.R.

, Oliveri

, Colombatto

, Capalbo

, Barbera

, Bonino

Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J Hepatol 1995; 22: 42–44.

14.

Brunetto

M.R.

, Oliveri

, Coco

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–270.

15.

EASL Clinical Practice Guidelines. Management of Chronic Hepatitis B. J Hepatol 2009; 50: 227–242.

16.

Lok

A.S.

, McMahon

B.J.

Chronic Hepatitis B: update 2009. Hepatology 2009; 50: 661–662.

17.

Carosi

, Rizzetto

Treatment of chronic hepatitis B: recommendations from an Italian workshop. Dig Liv Dis 2008; 40: 603–617.

18.

Hadziyannis

S.J.

, Papatheodoridis

G.V.

, Dimou

, Laras

, Papaioannou

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847–851.

19.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

E.J.

Long-term ttherapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673–2681.

20.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

E.J.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–1751.

21.

Chang

T.T.

, Lai

C.L.

, Kew Yoon

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen– positive chronic hepatitis B. Hepatology 2010; 51: 422–430.

22.

Gane

E.J.

, Wang

, Liaw

Y.F.

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011; 31: 676–684.

23.

Marcellin

, Lau

G.K.K.

, Bonino

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–1217.

24.

Piccolo

, Lenci

, Demelia

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14: 1165–1174.

25.

Sarin

S.K.

, Sood

, Kumar

Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96–104.

26.

Niro

G.A.

, Fontana

, Gioffreda

Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study. Dig Liver Dis 2007; 39: 857–863.

27.

Moucari

, Boyer

, Ripault

M.P.

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J Viral Hepat 2011; 18: 580–586.

28.

Zeuzem

, Gane

, Liaw

Y.F.

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11–20.

29.

Rijckborst

, Hansen

B.E.

, Cakaloglu

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454–461.

30.

Ishak

K.G.

Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113: 40–55.

31.

Chen

, Li

, Ye

Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011; 91: 23–31.

32.

Wursthorn

, Jung

, Riva

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients. Hepatology 2010; 52: 1611–1620.